Why is transesophageal echocardiography with a bubble‑contrast study not performed routinely in patients with acute pulmonary embolism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Why TEE with Bubble Study Is Not Standard in Acute PE

Transesophageal echocardiography with bubble-contrast study is not performed routinely in acute PE patients because it has limited diagnostic utility for PE itself, is semi-invasive requiring sedation, and is only selectively indicated for specific high-risk scenarios—primarily to detect patent foramen ovale (PFO) in massive/submassive PE or to identify right heart thrombi when considering surgical embolectomy.

Primary Diagnostic Limitations

TEE does not reliably diagnose or exclude PE. The test has poor sensitivity for visualizing pulmonary emboli, particularly in the left pulmonary artery where visualization is severely limited 1. Even when proximal thrombi are detected, the overall sensitivity for all pulmonary arterial thrombi is only 55% in patients with acute cor pulmonale 1. Standard transthoracic echocardiography (TTE) is normal in approximately 50% of unselected acute PE patients 2, and while TEE may improve sensitivity in critically ill patients, it cannot exclude PE when negative 1, 3.

CT pulmonary angiography (CTPA) is the established first-line imaging modality with high sensitivity and specificity for directly visualizing pulmonary emboli 4. TEE cannot compete with CTPA for diagnostic accuracy and provides no information about clot location or burden in the pulmonary arterial tree.

Selective Clinical Indications Where TEE Has Value

1. Screening for PFO in Massive/Submassive PE

The 2011 AHA Scientific Statement provides the clearest guidance: screening for PFO with echocardiography and bubble study may be considered (Class IIb) in patients with massive or submassive PE for risk stratification 5. This is because:

  • PFO presence in massive PE increases mortality risk 2.4-fold, ischemic stroke risk 5.9-fold, and peripheral arterial embolism risk 15-fold 5
  • Detection of impending paradoxical embolism (thrombus trapped within a PFO) may guide aggressive therapy including surgical embolectomy 5
  • PFO with PE increases risk of silent brain infarction (33% vs 2% without PFO) 5

However, this remains a Class IIb recommendation (may be considered), not a routine standard, because:

  • The optimal management strategy for PFO in PE remains unclear
  • Questions about how PFO detection should change PE management are unanswered
  • Timing of interventions (IVC filter placement, PFO closure) is not established 5

2. Detection of Right Heart Thrombi

When right heart thrombi or paradoxical embolism are suspected, TEE becomes the technique of choice to guide surgical decision-making 6. This is a specific, high-risk scenario rather than routine practice.

3. Hemodynamically Unstable Patients

In catastrophically unstable patients where CTPA is not immediately available or the patient cannot be transported, bedside TEE may provide rapid confirmation of massive PE to justify immediate thrombolysis or embolectomy 2, 7, 3. The 2008 ESC guidelines note that in highly unstable patients, PE diagnosis may be accepted based on compatible echocardiographic findings alone when other tests are unavailable 7.

Practical Barriers to Routine Use

  • Semi-invasive procedure: Requires conscious sedation, NPO status, and carries procedural risks
  • Resource intensive: Needs specialized equipment and trained operators
  • Time-consuming: Not practical for routine screening in all PE patients
  • Better alternatives exist: TTE provides similar prognostic information (RV dysfunction) non-invasively, and CTPA provides superior diagnostic accuracy 2

What Should Be Done Instead

For routine PE evaluation:

  • Standard TTE (without TEE) adequately assesses RV dysfunction for risk stratification 2, 8
  • RV/LV ratio >1.0 on TTE or CTPA identifies high-risk patients 8
  • CTPA remains the diagnostic gold standard 4

Reserve TEE with bubble study for:

  • Massive PE with hemodynamic instability when considering aggressive interventions
  • Suspected right heart thrombi or impending paradoxical embolism
  • When surgical embolectomy is being considered and intracardiac thrombus detection would alter management
  • Patients who cannot undergo CTPA and have echocardiographic signs of severe RV dysfunction

The 2019 ESC guidelines 8 and 2022 ACR Appropriateness Criteria 4 do not support routine TEE for suspected PE, reinforcing that it remains a selective tool for specific high-risk scenarios rather than standard practice.

References

4
Guideline

acr appropriateness criteria® suspected pulmonary embolism: 2022 update.

Journal of the American College of Radiology, 2022

Related Questions

What is the recommended work‑up and initial management for a patient with suspected pulmonary embolism on chest X‑ray?
What is the recommended duration of anticoagulation for pulmonary embolism?
What is the recommended management of pulmonary embolism?
What is the appropriate management of acute pulmonary embolism?
What are the clinical presentation and diagnostic approach for pulmonary embolism?
Having had a recent pulmonary embolism, does the fact that a patent foramen ovale is found in about one-third of patients mean I have a 33% risk of stroke?
Can you explain in plain terms what a patent foramen ovale (PFO) is, especially in the context of a recent pulmonary embolism?
Would a patent foramen ovale have been detected by the tests I underwent, such as a computed tomography pulmonary angiogram, standard chest X‑ray, and routine transthoracic echocardiogram?
After being off lamotrigine 150 mg daily for four days, should I restart at 25 mg or resume the previous dose?
In a patient whose echocardiogram with color‑flow Doppler shows no intracardiac shunt, what does this mean for the risk of paradoxical embolism and how should venous thrombosis be managed?
In the absence of an intracardiac shunt, what risks are associated with migrating clot fragments?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.